Literature DB >> 25070103

Efficacy of PTX3 and posaconazole combination in a rat model of invasive pulmonary aspergillosis.

Emanuele Marra1, Vitor L Sousa2, Roberta Gaziano3, M Lucrezia Pacello4, Brunilde Arseni4, Luigi Aurisicchio4, Rita De Santis5, Giovanni Salvatori5.   

Abstract

Posaconazole is currently used for the prophylaxis of invasive pulmonary aspergillosis (IPA). Limitations to posaconazole usage are drug-drug interactions and side effects. PTX3 is an innate immunity glycoprotein with opsonic activity, proven to be protective in IPA animal models. This study investigated the combination of posaconazole with PTX3. The results indicate synergy between PTX3 and posaconazole against aspergillosis, suggesting that a combination of reduced doses of posaconazole with the immune response enhancer PTX3 might represent a treatment option with a higher therapeutic index than posaconazole.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25070103      PMCID： PMC4187902          DOI： 10.1128/AAC.03038-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

Review 2.  Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility.

Authors:  Cecilia Garlanda; Barbara Bottazzi; Antonio Bastone; Alberto Mantovani
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

3.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

5.  Efficacy of PTX3 in a rat model of invasive aspergillosis.

Authors:  Pietro Lo Giudice; Silvia Campo; Antonio Verdoliva; Vincenzo Rivieccio; Franco Borsini; Rita De Santis; Giovanni Salvatori
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 6.  The pathobiology of Aspergillus fumigatus.

Authors:  J P Latgé
Journal:  Trends Microbiol       Date:  2001-08       Impact factor: 17.079

Review 7.  Pulmonary aspergillosis: a clinical update.

Authors:  O S Zmeili; A O Soubani
Journal:  QJM       Date:  2007-06

8.  IL-1 inducible genes in human umbilical vein endothelial cells.

Authors:  M Introna; F Breviario; E M d'Aniello; J Golay; E Dejana; A Mantovani
Journal:  Eur Heart J       Date:  1993-12       Impact factor: 29.983

9.  Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals.

Authors:  Roberta Gaziano; Silvia Bozza; Silvia Bellocchio; Katia Perruccio; Claudia Montagnoli; Lucia Pitzurra; Giovanni Salvatori; Rita De Santis; Paolo Carminati; Alberto Mantovani; Luigina Romani
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

10.  The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps.

Authors:  Sébastien Jaillon; Giuseppe Peri; Yves Delneste; Isabelle Frémaux; Andrea Doni; Federica Moalli; Cecilia Garlanda; Luigina Romani; Hugues Gascan; Silvia Bellocchio; Silvia Bozza; Marco A Cassatella; Pascale Jeannin; Alberto Mantovani
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307
View more
  6 in total

1.  Genetic variation and fungal infection risk: State of the art.

Authors:  Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-11-27

Review 2.  Paving the way for predictive diagnostics and personalized treatment of invasive aspergillosis.

Authors:  Ana Oliveira-Coelho; Fernando Rodrigues; António Campos; João F Lacerda; Agostinho Carvalho; Cristina Cunha
Journal:  Front Microbiol       Date:  2015-05-05       Impact factor: 5.640

3.  Pentraxin 3 (PTX-3) Levels in Bronchoalveolar Lavage Fluid as a Lung Cancer Biomarker.

Authors:  Tinghua Hu; LiBang Qiao; Hong Li; Hui Ren; Qian Ning; Hong Zhou; Xue Chen; Zhongmin Sun; Liangrong Shen
Journal:  Dis Markers       Date:  2020-06-10       Impact factor: 3.434

Review 4.  The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis.

Authors:  Rémi Porte; Sadaf Davoudian; Fatemeh Asgari; Raffaella Parente; Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

5.  Antifungal Effect of All-trans Retinoic Acid against Aspergillus fumigatus In Vitro and in a Pulmonary Aspergillosis In Vivo Model.

Authors:  Elena Campione; Roberta Gaziano; Emanuele Marra; Augusto Orlandi; Elena Doldo; Daniele Marino; Mattia Falconi; Federico Iacovelli; Daniela Tagliaferri; Lucrezia Pacello; Luca Bianchi; Caterina Lanna; Luigi Aurisicchio; Federica Centofanti; Paolo Di Francesco; Ilaria Del Principe; Francesca Del Bufalo; Franco Locatelli; Enrico Salvatore Pistoia
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 6.  Complementary Roles of Short and Long Pentraxins in the Complement-Mediated Immune Response to Aspergillus fumigatus Infections.

Authors:  Raffaella Parente; Valentina Possetti; Marco Erreni; Francesca D'Autilia; Barbara Bottazzi; Cecilia Garlanda; Alberto Mantovani; Antonio Inforzato; Andrea Doni
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.